Sandoz opens second state-of-the-art manufacturing plant in Boucherville

    Additional capacity will support growth and create 98 new positions

    BOUCHERVILLE, QC, Sept. 9 /CNW Telbec/ - Sandoz Canada today announced
the opening of its second manufacturing plant in Boucherville, Québec, to meet
growing demand for its generic sterile products in Canada and in other markets
around the world. The creation of this new plant, along with the modernization
of existing facilities in Boucherville, are the final pieces of a
CND $80 million investment program, announced last year, that will enhance the
company's production capacity by 66 per cent and give it leading-edge
facilities in Canada.
    "Sandoz has, in recent years, established itself as a global leader in
"difficult-to-make" products, such as the complex sterile products that will
be made in this site," commented Andreas Rummelt, Sandoz CEO. "This new site
indicates the company's commitment to providing our customers worldwide with a
wide range of medicines of the highest quality, it reflects on the great team
in the site who are producing such good results and is a sign of our
commitment to Québec and to Boucherville."
    Pierre Fréchette, President and CEO of Sandoz Canada, added: "We are one
of Canada's fastest growing pharmaceutical manufacturers and this new
production plant fits into our growth strategy as a Sandoz Center of
Excellence in the manufacture of complex sterile products. It means that we
will be able to meet expanding demand for existing products and to launch
exciting new medicines."
    To maintain its position as a top performing production facility,
50,000 square feet have been added at Boucherville for manufacturing,
warehousing and administrative support. With advanced equipment and three new
production lines, the new plant will give Sandoz Canada the manufacturing
capacity it needs to keep pace with demand.
    "The inauguration of the new site is the culmination of a great deal of
hard work by Sandoz Canada employees and reflects the collaboration of
suppliers, partners and the local community," concluded Pierre Fréchette. "We
would particularly like to acknowledge the support of Emploi-Québec, which is
helping us with the hiring and training of 98 new employees in the highly
regulated and very complicated business of sterile product manufacture, as
well as with training and development for existing employees at the site."
    The opening of the new facilities was attended by Raymond Bachand,
Provincial Minister of Economic Development, Innovation and Export Trade,
Minister of Tourism and Minister responsible for the Montreal Region, as well
as Francine Gadbois, Mayoress of Boucherville. A number of distinguished
guests from the province's medical, political and business communities were
also present.

    About Sandoz Canada

    The Boucherville site has built a strong reputation among the Novartis
Group of companies for managing the unique product development challenges
associated with generic sterile products. Sandoz Canada develops,
manufactures, markets and distributes a broad range of generic
pharmaceuticals. Its portfolio includes narcotics, sedatives, antibiotics,
ophthalmics, hormones treatments, corticosteroids and cardiology drugs that
are produced in various dosage forms: injectables, ampoules and vials;
ophthalmic solutions, suspensions and ointments; suppositories and oral and
topical preparations.
    Sandoz Canada employs about 680 people, most of whom are based at the
Boucherville facilities.

    About Sandoz

    Sandoz, a Division of the Novartis group, is a global leader in the field
of generic pharmaceuticals, offering a wide array of high-quality, affordable
products that are no longer protected by patents. Sandoz has a portfolio of
more than 950 compounds and sells its products in more than 130 countries. Key
product groups include antibiotics, treatments for central nervous system
disorders, gastrointestinal medicines, cardiovascular treatments and hormone
therapies. Sandoz develops, produces and markets these medicines along with
pharmaceutical and biotechnological active substances and anti-infectives. In
addition to strong organic growth in recent years, Sandoz has made a series of
acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany) and Eon
Labs (US). In 2007, Sandoz employed around 23,000 people worldwide and posted
sales of USD 7.2 billion.

    /NOTE TO PHOTO EDITORS: A photo accompanying this release is available on
    the CNW Photo Network and archived at
    Additional archived images are also available on the CNW Photo Archive
    website at Images are free to accredited
    members of the media/

For further information:

For further information: Monika Sniec, Communications Manager, Sandoz
Canada, (450) 641-4903 ext. 2518, Fax: (450) 641-3170; Carol Sharpe, NATIONAL
Public Relations, (514) 843-2368

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890